A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Summit Therapeutics' ivonescimab performed well in a phase 3 study. The cancer drug candidate is licensed from a Chinese ...

Taletrectinib can be effective in patients with TKI-naïve or TKI-pretreated advanced NSCLC, a pooled analysis suggests.

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit ...

Williams, 70, has to pay nearly $180,000 for his cancer therapy, of which more than $25,000 will go on GST. “It’s a tax on ...

Scientists at Ankara University have developed an AI tool that detects early-stage lung cancer with over 90% accuracy by ...

A large study found that people whose biological age exceeds their chronological age are about 30% more likely to develop ...

CHINO HILLS, CA / ACCESS Newswire / May 2, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces ...

RayStation v2025 integrates the auto-planning algorithm ECHO. The ECHO algorithm optimizes the treatment plan based on pre-defined planning protocols designed for various clinical indications. The ...